Galimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing oral and topical small-molecule therapies for neurodegenerative diseases of the eye and brain. Its lead candidate, GAL-101, targets misfolded amyloid beta before toxic oligomers form and is being studied as an eye drop for geographic atrophy, an advanced form of dry age-related macular degeneration. The company’s approach also supports planned development in glaucoma and Alzheimer’s disease, with ophthalmology commercialization backed by Théa Open Innovation.
Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY
Outlook Therapeutics, IncOutlook Therapeutics is a biopharmaceutical company developing and commercializing ophthalmic therapies for retinal diseases, centered on LYTENAVA™ (bevacizumab-vikg) for neovascular, or wet, age-related macular degeneration. LYTENAVA is the first and only FDA-approved ophthalmic bevacizumab formulation for wet AMD in the United States, and is also authorized for the same use in the European Union and United Kingdom. The company is building on its clinical development experience to expand access to ophthalmic bevacizumab and pursue additional retinal-disease applications.ISELIN, NJ
Clene Nanomedicine, IncClene Nanomedicine is a clinical-stage biopharmaceutical company co-founded in 2013 and focused on developing treatments for neurodegenerative disease. Its patented electro-crystal-chemistry process produces clean-surfaced nanocrystals, including the investigational gold-based candidate CNM-Au8 for people living with ALS.NORTH EAST, MD
Amyndas PharmaceuticalsFounded by University of Pennsylvania complement researcher John D. Lambris, Amyndas Pharmaceuticals develops C3-targeted complement therapeutics for inflammatory and immune-mediated diseases. The company’s patented platform builds on compstatin, the peptide inhibitor discovered in Lambris’ laboratory, with lead programs including AMY-101 and newer candidates designed for longer-lasting treatment of conditions such as age-related macular degeneration.PHILADELPHIA, PA